Details of the Drug

General Information of Drug (ID: DMINOX3)

Drug Name
Vincristine
Synonyms
LCR; Leurocristine; Marqibo; Oncovine; Tecnocris; VCR; VIN; Vincasar; Vincristina; Vincristinum; Vincrstine; Vincrystine; Vinkristin; Indole alkaloid; Liposomal Vincristine; Onco TCS; Vincristina [DCIT]; Oncovin (TN); Tecnocris (TN); Vincristine (INN); Vincristine [INN:BAN]; Vincristinum [INN-Latin]; Lilly37231 (1:1 sulfate salt); Oncovin (1:1 sulfate salt); Vincasar (1:1 sulfate salt); Vincrex (1:1 sulfate salt); Vincaleukoblastine, 22-oxo-22-Oxovincaleukoblastine; Z-D-Val-Lys(Z)-OH; 22-Oxovincaleukoblastine
Indication
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Approved [1], [2]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 825
Topological Polar Surface Area (xlogp) 2.8
Rotatable Bond Count (rotbonds) 10
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 12
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 2 mL/min/kg [4]
Elimination
15% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 5 minutes (alpha), 2.3 hours (beta), and 85 hours (gamma) [4]
Metabolism
The drug is metabolized via the hepatic [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.4% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 2.4 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 10 mg/mL [3]
Chemical Identifiers
Formula
C46H56N4O10
IUPAC Name
methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
Canonical SMILES
CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O
InChI
InChI=1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1
InChIKey
OGWKCGZFUXNPDA-XQKSVPLYSA-N
Cross-matching ID
PubChem CID
5978
ChEBI ID
CHEBI:28445
CAS Number
57-22-7
DrugBank ID
DB00541
TTD ID
D09QVV
VARIDT ID
DR00143
INTEDE ID
DR1692

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tubulin beta (TUBB) TTYFKSZ NOUNIPROTAC Modulator [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [7]
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [8]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [9]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [11]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [11]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Vincristine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Vincristine and Clofarabine. Mature B-cell lymphoma [2A85] [77]
Blinatumomab DMGECIJ Moderate Decreased metabolism of Vincristine caused by Blinatumomab mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [78]
Coadministration of a Drug Treating the Disease Different from Vincristine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Vincristine and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [79]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Vincristine caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [80]
Midostaurin DMI6E0R Moderate Decreased clearance of Vincristine due to the transporter inhibition by Midostaurin. Acute myeloid leukaemia [2A60] [81]
Arn-509 DMT81LZ Moderate Accelerated clearance of Vincristine due to the transporter induction by Arn-509. Acute myeloid leukaemia [2A60] [81]
Gilteritinib DMWQ4MZ Moderate Decreased clearance of Vincristine due to the transporter inhibition by Gilteritinib. Acute myeloid leukaemia [2A60] [82]
Siltuximab DMGEATB Moderate Additive immunosuppressive effects by the combination of Vincristine and Siltuximab. Anemia [3A00-3A9Z] [81]
Dronedarone DMA8FS5 Moderate Decreased clearance of Vincristine due to the transporter inhibition by Dronedarone. Angina pectoris [BA40] [83]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Vincristine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [84]
Voriconazole DMAOL2S Major Decreased clearance of Vincristine due to the transporter inhibition by Voriconazole. Aspergillosis [1F20] [85]
Posaconazole DMUL5EW Major Decreased clearance of Vincristine due to the transporter inhibition by Posaconazole. Aspergillosis [1F20] [85]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Vincristine and Roflumilast. Asthma [CA23] [81]
Ofloxacin DM0VQN3 Minor Decreased absorption of Vincristine due to intestinal mucosa variation caused by Ofloxacin. Bacterial infection [1A00-1C4Z] [86]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Vincristine caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [87]
Clarithromycin DM4M1SG Major Decreased clearance of Vincristine due to the transporter inhibition by Clarithromycin. Bacterial infection [1A00-1C4Z] [85]
Trovafloxacin DM6AN32 Minor Decreased absorption of Vincristine due to intestinal mucosa variation caused by Trovafloxacin. Bacterial infection [1A00-1C4Z] [86]
Sparfloxacin DMB4HCT Minor Decreased absorption of Vincristine due to intestinal mucosa variation caused by Sparfloxacin. Bacterial infection [1A00-1C4Z] [86]
Gemifloxacin DMHT34O Minor Decreased absorption of Vincristine due to intestinal mucosa variation caused by Gemifloxacin. Bacterial infection [1A00-1C4Z] [86]
Norfloxacin DMIZ6W2 Minor Decreased absorption of Vincristine due to intestinal mucosa variation caused by Norfloxacin. Bacterial infection [1A00-1C4Z] [86]
ABT-492 DMJFD2I Minor Decreased absorption of Vincristine due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [86]
Levofloxacin DMS60RB Minor Decreased absorption of Vincristine due to intestinal mucosa variation caused by Levofloxacin. Bacterial infection [1A00-1C4Z] [86]
Troleandomycin DMUZNIG Major Decreased clearance of Vincristine due to the transporter inhibition by Troleandomycin. Bacterial infection [1A00-1C4Z] [85]
Lomefloxacin DMVRH9C Minor Decreased absorption of Vincristine due to intestinal mucosa variation caused by Lomefloxacin. Bacterial infection [1A00-1C4Z] [86]
Telithromycin DMZ4P3A Major Decreased clearance of Vincristine due to the transporter inhibition by Telithromycin. Bacterial infection [1A00-1C4Z] [85]
Erdafitinib DMI782S Moderate Decreased clearance of Vincristine due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [88]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Vincristine and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [89]
Lomustine DMMWSUL Minor Decreased metabolism of Vincristine caused by Lomustine mediated inhibition of CYP450 enzyme. Brain cancer [2A00] [90]
Lapatinib DM3BH1Y Moderate Decreased clearance of Vincristine due to the transporter inhibition by Lapatinib. Breast cancer [2C60-2C6Y] [91]
Tucatinib DMBESUA Major Decreased clearance of Vincristine due to the transporter inhibition by Tucatinib. Breast cancer [2C60-2C6Y] [85]
Palbociclib DMD7L94 Moderate Decreased metabolism of Vincristine caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [92]
Capecitabine DMTS85L Minor Increased plasma concentrations of Vincristine and Capecitabine due to competitive inhibition of the same metabolic pathway. Colorectal cancer [2B91] [90]
Mifepristone DMGZQEF Moderate Decreased metabolism of Vincristine caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [81]
Ivacaftor DMZC1HS Moderate Decreased clearance of Vincristine due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [93]
MK-8228 DMOB58Q Moderate Decreased metabolism of Vincristine caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [94]
Aprepitant DM053KT Moderate Decreased metabolism of Vincristine caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [95]
Nefazodone DM4ZS8M Major Decreased metabolism of Vincristine caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [85]
Primidone DM0WX6I Moderate Increased metabolism of Vincristine caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [96]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Vincristine caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [97]
Cenobamate DMGOVHA Moderate Increased metabolism of Vincristine caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [98]
Fosphenytoin DMOX3LB Moderate Accelerated clearance of Vincristine due to the transporter induction by Fosphenytoin. Epilepsy/seizure [8A61-8A6Z] [99]
Rufinamide DMWE60C Moderate Increased metabolism of Vincristine caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [81]
Phenobarbital DMXZOCG Moderate Increased metabolism of Vincristine caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [96]
Carbamazepine DMZOLBI Moderate Accelerated clearance of Vincristine due to the transporter induction by Carbamazepine. Epilepsy/seizure [8A61-8A6Z] [96]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Vincristine and Cannabidiol. Epileptic encephalopathy [8A62] [81]
Tazemetostat DMWP1BH Moderate Increased metabolism of Vincristine caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [100]
Itraconazole DMCR1MV Major Decreased metabolism of Vincristine caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [85]
Miconazole DMPMYE8 Moderate Decreased metabolism of Vincristine caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [101]
Ketoconazole DMPZI3Q Major Decreased metabolism of Vincristine caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [85]
Boceprevir DMBSHMF Major Decreased metabolism of Vincristine caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [85]
Telaprevir DMMRV29 Major Decreased clearance of Vincristine due to the transporter inhibition by Telaprevir. Hepatitis virus infection [1E50-1E51] [85]
Rifampin DMA8J1G Moderate Accelerated clearance of Vincristine due to the transporter induction by Rifampin. HIV-infected patients with tuberculosis [1B10-1B14] [96]
Rifapentine DMCHV4I Moderate Accelerated clearance of Vincristine due to the transporter induction by Rifapentine. HIV-infected patients with tuberculosis [1B10-1B14] [96]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Vincristine and Brentuximab vedotin. Hodgkin lymphoma [2B30] [102]
Delavirdine DM3NF5G Major Decreased metabolism of Vincristine caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [85]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Vincristine caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [85]
Cobicistat DM6L4H2 Major Decreased clearance of Vincristine due to the transporter inhibition by Cobicistat. Human immunodeficiency virus disease [1C60-1C62] [85]
Efavirenz DMC0GSJ Moderate Increased metabolism of Vincristine caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [103]
Saquinavir DMG814N Major Decreased metabolism of Vincristine caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [85]
Etravirine DMGV8QU Moderate Increased metabolism of Vincristine caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [104]
Zalcitabine DMH7MUV Moderate Increased risk of peripheral neuropathy by the combination of Vincristine and Zalcitabine. Human immunodeficiency virus disease [1C60-1C62] [105]
Amprenavir DMLMXE0 Major Decreased metabolism of Vincristine caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [85]
Darunavir DMN3GCH Moderate Decreased metabolism of Vincristine caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [106]
Atazanavir DMSYRBX Major Decreased metabolism of Vincristine caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [85]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Vincristine and Mipomersen. Hyper-lipoproteinaemia [5C80] [107]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Vincristine and Teriflunomide. Hyper-lipoproteinaemia [5C80] [108]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Vincristine and BMS-201038. Hyper-lipoproteinaemia [5C80] [109]
Verapamil DMA7PEW Minor Increased plasma concentration of Vincristine and Verapamil due to competitive binding of plasma proteins. Hypertension [BA00-BA04] [110]
Conivaptan DM1V329 Major Decreased metabolism of Vincristine caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [85]
Tolvaptan DMIWFRL Moderate Decreased clearance of Vincristine due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [82]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Vincristine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [111]
Amobarbital DM0GQ8N Moderate Increased metabolism of Vincristine caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [96]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Vincristine and Methotrexate. Leukaemia [2A60-2B33] [81]
Glycerol phenylbutyrate DMDGRQO Moderate Increased metabolism of Vincristine caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme. Liver disease [DB90-DB9Z] [81]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of Vincristine and Denosumab. Low bone mass disorder [FB83] [112]
Crizotinib DM4F29C Moderate Decreased metabolism of Vincristine caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [113]
Brigatinib DM7W94S Moderate Increased metabolism of Vincristine caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [114]
Ceritinib DMB920Z Major Decreased metabolism of Vincristine caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [85]
PF-06463922 DMKM7EW Moderate Increased metabolism of Vincristine caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [115]
Osimertinib DMRJLAT Moderate Increased metabolism of Vincristine caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [81]
Capmatinib DMYCXKL Moderate Decreased clearance of Vincristine due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [116]
Selpercatinib DMZR15V Moderate Decreased metabolism of Vincristine caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [81]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Vincristine and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [117]
Idelalisib DM602WT Major Decreased metabolism of Vincristine caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [85]
IPI-145 DMWA24P Moderate Decreased metabolism of Vincristine caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [118]
LGX818 DMNQXV8 Moderate Increased metabolism of Vincristine caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [119]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Vincristine caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [81]
Lasmiditan DMXLVDT Moderate Decreased clearance of Vincristine due to the transporter inhibition by Lasmiditan. Migraine [8A80] [120]
Exjade DMHPRWG Moderate Decreased metabolism of Vincristine caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [121]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of Vincristine and Thalidomide. Multiple myeloma [2A83] [122]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Vincristine and Tecfidera. Multiple sclerosis [8A40] [123]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Vincristine and Siponimod. Multiple sclerosis [8A40] [82]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Vincristine and Fingolimod. Multiple sclerosis [8A40] [124]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Vincristine and Ocrelizumab. Multiple sclerosis [8A40] [125]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Vincristine and Ozanimod. Multiple sclerosis [8A40] [81]
Rifabutin DM1YBHK Moderate Increased metabolism of Vincristine caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [96]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Vincristine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [81]
Nilotinib DM7HXWT Moderate Decreased clearance of Vincristine due to the transporter inhibition by Nilotinib. Myeloproliferative neoplasm [2A20] [126]
Imatinib DM7RJXL Moderate Decreased metabolism of Vincristine caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [127]
Dasatinib DMJV2EK Moderate Decreased metabolism of Vincristine caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [128]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Vincristine and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [129]
Modafinil DMYILBE Minor Increased metabolism of Vincristine caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [130]
Rolapitant DM8XP26 Moderate Decreased clearance of Vincristine due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [131]
Entrectinib DMMPTLH Moderate Decreased metabolism of Vincristine caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [132]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Vincristine caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [133]
Abametapir DM2RX0I Moderate Decreased metabolism of Vincristine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [134]
Lefamulin DME6G97 Moderate Decreased metabolism of Vincristine caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [135]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Vincristine caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [85]
Enzalutamide DMGL19D Moderate Accelerated clearance of Vincristine due to the transporter induction by Enzalutamide. Prostate cancer [2C82] [136]
Ustekinumab DMHTYK3 Moderate Additive myelosuppressive effects by the combination of Vincristine and Ustekinumab. Psoriasis [EA90] [81]
Tildrakizumab DMLW9HG Moderate Additive myelosuppressive effects by the combination of Vincristine and Tildrakizumab. Psoriasis [EA90] [81]
Risankizumab DMM32GT Moderate Additive immunosuppressive effects by the combination of Vincristine and Risankizumab. Psoriasis [EA90] [81]
Ixekizumab DMXW92T Moderate Additive myelosuppressive effects by the combination of Vincristine and Ixekizumab. Psoriasis [EA90] [81]
Bosentan DMIOGBU Moderate Increased metabolism of Vincristine caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [137]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Vincristine and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [138]
Gatifloxacin DMSL679 Minor Decreased absorption of Vincristine due to intestinal mucosa variation caused by Gatifloxacin. Respiratory infection [CA07-CA4Z] [86]
Tocilizumab DM7J6OR Moderate Additive immunosuppressive effects by the combination of Vincristine and Tocilizumab. Rheumatoid arthritis [FA20] [81]
Canakinumab DM8HLO5 Moderate Additive myelosuppressive effects by the combination of Vincristine and Canakinumab. Rheumatoid arthritis [FA20] [81]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Vincristine and Rilonacept. Rheumatoid arthritis [FA20] [81]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Vincristine and Golimumab. Rheumatoid arthritis [FA20] [139]
Dexamethasone DMMWZET Moderate Increased metabolism of Vincristine caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [96]
Sarilumab DMOGNXY Moderate Additive myelosuppressive effects by the combination of Vincristine and Sarilumab. Rheumatoid arthritis [FA20] [81]
Leflunomide DMR8ONJ Major Additive myelosuppressive effects by the combination of Vincristine and Leflunomide. Rheumatoid arthritis [FA20] [108]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Vincristine when combined with Anthrax vaccine. Sepsis [1G40-1G41] [140]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Vincristine caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [141]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Vincristine caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [81]
Larotrectinib DM26CQR Moderate Decreased metabolism of Vincristine caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [82]
Armodafinil DMGB035 Minor Increased metabolism of Vincristine caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [130]
LEE011 DMMX75K Moderate Decreased metabolism of Vincristine caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [142]
Etoposide DMNH3PG Minor Decreased metabolism of Vincristine caused by Etoposide mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [90]
Fluorouracil DMUM7HZ Minor Increased plasma concentrations of Vincristine and Fluorouracil due to competitive inhibition of the same metabolic pathway. Solid tumour/cancer [2A00-2F9Z] [90]
Doxorubicin DMVP5YE Minor Decreased metabolism of Vincristine caused by Doxorubicin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [90]
Pitolisant DM8RFNJ Moderate Increased metabolism of Vincristine caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [81]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Vincristine and Naltrexone. Substance abuse [6C40] [143]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Vincristine caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [144]
Brilinta DMBR01X Moderate Decreased metabolism of Vincristine caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [81]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Vincristine and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [138]
Azathioprine DMMZSXQ Moderate Additive myelosuppressive effects by the combination of Vincristine and Azathioprine. Transplant rejection [NE84] [82]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Vincristine and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [138]
Cinoxacin DM4EWNS Minor Decreased absorption of Vincristine due to intestinal mucosa variation caused by Cinoxacin. Urinary tract infection [GC08] [86]
Nalidixic acid DMRM0JV Minor Decreased absorption of Vincristine due to intestinal mucosa variation caused by Nalidixic acid. Urinary tract infection [GC08] [86]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Vincristine and Ganciclovir. Virus infection [1A24-1D9Z] [82]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Vincristine and Valganciclovir. Virus infection [1A24-1D9Z] [82]
⏷ Show the Full List of 141 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6785).
2 Vinflunine, a novel microtubule inhibitor, suppresses calmodulin interaction with the microtubule-associated protein STOP. Biochemistry. 2007 Dec 25;46(51):14899-906.
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
8 Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur J Pharmacol. 2008 Sep 4;591(1-3):128-31.
9 Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
10 L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines. Toxicol Lett. 2010 Feb 15;192(3):408-18.
11 Association of CYP3A5 expression and vincristine neurotoxicity in pediatric malignancies in Turkish population. J Pediatr Hematol Oncol. 2017 Aug;39(6):458-462.
12 Drug Interactions Flockhart Table
13 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
14 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
15 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
16 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
17 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
18 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
19 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
20 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
21 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
22 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
23 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
24 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
25 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
26 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
27 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
28 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
29 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
30 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
31 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
32 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
33 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
34 The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer. 2005 Jul 11;93(1):89-97.
35 Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
36 Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
37 Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001 Oct;8(10):803-14.
38 Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.
39 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
40 ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
41 Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab Dispos. 2008 Dec;36(12):2571-81.
42 Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology. 2010 Jun;58(7):1019-32.
43 Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
44 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
45 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
46 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
47 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
48 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
49 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
50 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
51 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
52 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
53 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
54 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
55 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
56 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
57 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
58 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
59 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
60 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
61 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
62 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
63 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
64 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
65 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
66 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
67 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
68 Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitol Int. 2009 Sep;58(3):270-7.
69 Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells. Anticancer Res. 2007 Mar-Apr;27(2):729-36.
70 Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
71 NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 2006 Jan;17(1):25-31.
72 Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. J Med Chem. 2001 Oct 25;44(22):3599-605.
73 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
74 Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7.
75 The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.Cancer Biol Ther.2014;15(11):1552-60.
76 National Cancer Institute Drug Dictionary (drug id 598799).
77 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
78 Product Information. Blincyto (blinatumomab). Amgen USA, Thousand Oaks, CA.
79 European Medicines Agency "Summary on compassionate use. Remdesivir Gilead.".
80 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
81 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
82 Cerner Multum, Inc. "Australian Product Information.".
83 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
84 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
85 Antoniou T, Tseng AL "Interactions between antiretrovirals and antineoplastic drug therapy." Clin Pharmacokinet 44 (2005): 111-145. [PMID: 15656694]
86 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
87 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
88 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
89 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
90 Product Information. Oncovin (vincristine). Lilly, Eli and Company, Indianapolis, IN.
91 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
92 Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
93 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
94 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
95 Charasson V, Haaz MC, Robert J "Determination of Drug Interactions Occurring with the Metabolic Pathways of Irinotecan." Drug Metab Dispos 30 (2002): 731-733. [PMID: 12019202]
96 Product Information. Marqibo (vinCRIStine liposome). Talon Therapeutics Inc, South San Francisco,, CA.
97 Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
98 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
99 Bollini P, Riva R, Albani F, Ida et al "Decreased phenytoin level during antineoplastic therapy: a case report." Epilepsia 24 (1983): 75-8. [PMID: 6822234]
100 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
101 Product Information. ORAVIG (miconazole). Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.
102 Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
103 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
104 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
105 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
106 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
107 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
108 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
109 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
110 Abdel-Rahman M, Wosch F, Harder S, Woodcock BG "Interaction between verapamil and vincristine binding to plasma proteins." Int J Clin Pharmacol Ther Toxicol 30 (1992): 536-7. [PMID: 1490822]
111 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
112 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
113 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
114 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
115 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
116 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
117 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
118 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
119 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
120 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
121 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
122 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
123 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
124 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
125 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
126 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
127 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
128 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
129 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
130 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
131 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
132 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
133 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
134 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
135 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
136 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
137 Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
138 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
139 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
140 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
141 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
142 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
143 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
144 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.